Castration-resistant prostate cancer deals continue to trickle: Data Byte

Deal activity in castration-resistant prostate cancer (CRPC) continues to be quiet this year, with two clinical partnerships disclosed so far. 

Both of the deals involved combination trials with the small molecule androgen receptor inhibitor EPI-7386 from Essa Pharma Inc. (NASDAQ:EPIX). In February, Essa partnered with  Astellas Pharma Inc. (Tokyo:4503) to test EPI-7386 in combination with Xtandi enzalutamide, and in April, the biotech partnered with Bayer AG (Xetra:BAYN) to test EPI-7386 in combination with Nubeqa darolutamide (BAY1841788, BAY-1841788, ODM-201)...